Program
Clopidogrel
Also written as “clopidogrel”, “clopidogrel (SR25990C)” and “Clopidogrel (SR25990)”.
Its studies are mostly in Coronary Artery Disease · Cardiovascular Diseases · Acute Coronary Syndrome · Heart Defects, Congenital · Diabetes Mellitus, Type 2, led by 17 companies.
Drug pageClopidogrel: every studyMany companies study it; this page follows only the 55 they lead. All 341 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sanofiits history only | 250 open or running | phase 4since Feb 23, 2006 | Dec 20, 2002 | none ahead |
| Dr. Reddy's Laboratoriesits history only | 40 open or running | phase 1since Jan 6, 2012 | Jan 6, 2012 | none ahead |
| AstraZenecaits history only | 30 open or running | phase 1since Jun 4, 2010 | Jun 4, 2010 | none ahead |
| Bristol-Myers Squibbits history only | 30 open or running | phase 1since Jul 8, 2009 | Jul 8, 2009 | none ahead |
| Eli Lillyits history only | 30 open or running | phase 2since Jul 26, 2006 | Jul 26, 2006 | none ahead |
| Viatrisits history only | 30 open or running | phase 1since Mar 30, 2008 | Mar 30, 2008 | none ahead |
| Johnson & Johnsonits history only | 20 open or running | phase 2since Nov 13, 2014 | Nov 13, 2014 | none ahead |
| Les Laboratoires des Médicaments Stérilesits history only | 20 open or running | phase 4since Aug 25, 2011 | Aug 25, 2011 | none ahead |
| Merckits history only | 20 open or running | phase 1since Nov 10, 2009 | Nov 10, 2009 | none ahead |
| Accumetricsits history only | 10 open or running | no phasesince Mar 24, 2008 | Mar 24, 2008 | none ahead |
| Boston Scientificits history only | 10 open or running | phase 4since May 1, 2012 | May 1, 2012 | none ahead |
| Cordisits history only | 10 open or running | phase 4since Aug 6, 2009 | Aug 6, 2009 | none ahead |
| Hanmi Pharmaceuticalits history only | 10 open or running | phase 4since Apr 5, 2013 | Apr 5, 2013 | none ahead |
| Laboratoires Teriakits history only | 10 open or running | phase 4since Oct 14, 2017 | Oct 14, 2017 | none ahead |
| Novo Nordiskits history only | 10 open or running | phase 1since May 16, 2012 | May 16, 2012 | none ahead |
| Otsuka | 10 open or running | phase 1since Sep 15, 2015 | Sep 15, 2015 | none ahead |
| Pharmtechnologyits history only | 10 open or running | phase 1since Jun 28, 2023 | Jun 28, 2023 | none ahead |
Also a collaborator on its studies: Bayer and Daiichi Sankyo.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Otsuka only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 15, 2015First study: phase 1 study in HealthyFirst studyNCT02554721 · 77 enrolled · Germany
TargetBeta
“Purinergic receptor P2Y12 antagonist; Purinergic receptor P2Y12 antagonist; Purinergic receptor P2Y12 antagonist; Purinergic receptor P2Y12 antagonist”ChEMBL 37, by rule
Other programs on P2RY12
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Ticagrelorrule | AstraZeneca | phase 4 | 47 |
| selatogrelrule | Viatris | phase 3 | 11 |
Studies
The one study Otsuka leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT02554721Healthy · Germany | 1 | Completed | Mar 30, 2018 | 77 |
How it is read
Names in the registry
- “Clopidogrel”, 41 entries
- “clopidogrel”, 11 entries
- “clopidogrel (SR25990C)”, 4 entries
- “Clopidogrel (SR25990)”, 3 entries
- “clopidogrel (SR25990)”, 3 entries
Conditions, from the studies’ own filings
- Coronary Artery Disease, 5 studies
- Cardiovascular Diseases, 4 studies
- Acute Coronary Syndrome, 3 studies
- Heart Defects, Congenital, 3 studies
- Diabetes Mellitus, Type 2, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.